相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile
Gamze Guney Eskiler et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2019)
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
R. de Haan et al.
BMC CANCER (2019)
PARP Inhibition in Cancer: An Update on Clinical Development
Esha Sachdev et al.
TARGETED ONCOLOGY (2019)
PARP1 is a versatile factor in the regulation of mRNA stability and decay
Elena A. Matveeva et al.
SCIENTIFIC REPORTS (2019)
Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome
David Lemchak et al.
EXPERIMENTAL DERMATOLOGY (2018)
PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia
Hossein Pashaiefar et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2018)
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
Rosemarie de Haan et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage
Lisa B. Caruso et al.
Oncotarget (2018)
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
Florian Engert et al.
ONCOTARGET (2017)
Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi
Marlena S. Fejzo et al.
GENES CHROMOSOMES & CANCER (2017)
Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways
Rajib Ghosh et al.
DNA REPAIR (2016)
Advanced-Stage Mycosis Fungoides and Sézary Syndrome: Survival and Response to Treatment
Silvia Alberti-Violetti et al.
Clinical Lymphoma Myeloma & Leukemia (2015)
Rapamycin Suppresses Tumor Growth and Alters the Metabolic Phenotype in T-Cell Lymphoma
Wasakorn Kittipongdaja et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
PARP-1 EXPRESSION IN CD34+LEUKEMIC CELLS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: RELATION TO RESPONSE TO INITIAL THERAPY AND OTHER PROGNOSTIC FACTORS
Agnieszka Kruk et al.
POLISH JOURNAL OF PATHOLOGY (2015)
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
Ashleigh Herriott et al.
ONCOTARGET (2015)
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sezary syndrome
Madeleine Duvic
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2015)
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
Eiji Kubota et al.
CELL CYCLE (2014)
Depletion of M2-Like Tumor-Associated Macrophages Delays Cutaneous T-Cell Lymphoma Development In Vivo
Xuesong Wu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Joyce F. Liu et al.
EUROPEAN JOURNAL OF CANCER (2013)
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Nicola J. Curtin et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Changing Incidence Trends of Cutaneous T-Cell Lymphoma
Kaveri Korgavkar et al.
JAMA DERMATOLOGY (2013)
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Matthew J. Schiewer et al.
CANCER DISCOVERY (2012)
Upregulation of Inflammatory Cytokines and Oncogenic Signal Pathways Preceding Tumor Formation in a Murine Model of T-Cell Lymphoma in Skin
Xuesong Wu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
PRDM1 is a tumor suppressor gene in natural killer cell malignancies
Can Kuecuek et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
M. Javle et al.
Therapeutic Advances in Medical Oncology (2011)
The potential role and application of PARP inhibitors in cancer treatment
Anthony J. Chalmers
BRITISH MEDICAL BULLETIN (2009)
Terminal differentiation of lymphocytes depends on Blimp-1
Axel Kallies et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Transcriptional repressor Blimp-1 regulates T cell homeostasis and function
GA Martins et al.
NATURE IMMUNOLOGY (2006)
Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance
A Kallies et al.
NATURE IMMUNOLOGY (2006)
Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome - Clinical prognostic factors and risk for disease progression
YH Kim et al.
ARCHIVES OF DERMATOLOGY (2003)
分享论文
